This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty—results from a randomized placebo-controlled clinical trial, Osteoporosis International, May 2022, Springer Science + Business Media,
DOI: 10.1007/s00198-022-06423-w.
You can read the full text:
The following have contributed to this page
